Literature DB >> 6653943

Circulating glucagon after total pancreatectomy in man.

J J Holst, J H Pedersen, F Baldissera, F Stadil.   

Abstract

In five totally pancreatectomized human subjects the secretion of gut-derived glucagons was stimulated by ingestion of a meal rich in fat and carbohydrates. Glucagon-like immunoreactivity in plasma, measured with an antiserum against the 6-15 sequence, increased fivefold in response to the meal. Glucagon like immunoreactivity measured with a antiserum against the C-terminal sequence was initially normal (12-13 pmol/l), increased slightly (to 20 pmol/l), and then decreased (to approximately 6 pmol/l). The chromatographic profile of glucagon-like immunoreactivity in plasma at maximum stimulation was studied after concentration by affinity chromatography. Both assay systems identified two peaks (at Kd-values of 0.30 and 0.60-0.65, and 0.30 and 0.70, respectively). The position at Kd 0.70 corresponds to that of glucagon 1-29. The same components may be identified in plasma from normal subjects. It is concluded that the human intestine is capable of generating all of the molecular forms of glucagon which normally are present in plasma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6653943     DOI: 10.1007/BF00282517

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  18 in total

1.  Production and evaluation of glucagon antibodies for radioimmunoassay.

Authors:  J J Holst; B Aasted
Journal:  Acta Endocrinol (Copenh)       Date:  1974-12

2.  Determination of gastrin in serum. An evaluation of the reliability of a radioimmunoassay.

Authors:  F Stadil; J F Rehfeld
Journal:  Scand J Gastroenterol       Date:  1973       Impact factor: 2.423

3.  Radioimmunological determination of pancreatic and gut glucagon in plasma.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1971-02       Impact factor: 10.122

4.  Stripping of endogenous ligands from antisera against glucagon.

Authors:  R Grønholt; J J Holst
Journal:  J Immunol Methods       Date:  1983-03-11       Impact factor: 2.303

5.  Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide.

Authors:  D Bataille; K Tatemoto; C Gespach; H Jörnvall; G Rosselin; V Mutt
Journal:  FEBS Lett       Date:  1982-09-06       Impact factor: 4.124

6.  C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.

Authors:  O K Faber; C Binder
Journal:  Diabetes       Date:  1977-07       Impact factor: 9.461

Review 7.  Extrapancreatic glucagons.

Authors:  J J Holst
Journal:  Digestion       Date:  1978       Impact factor: 3.216

8.  Absence of true pancreatic glucagon but persistence of circulating pancreatic glucagon-like immunoreactivity after pancreatectomy in pigs.

Authors:  J J Holst; M Kreutzfeldt; G Holm; E Jensen; J S Poulsen; B Sparsö; B Sparsö; A Schmidt
Journal:  Diabete Metab       Date:  1978-06

9.  Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours.

Authors:  J J Holst
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

10.  Extraction, gel filtration pattern, and receptor binding of porcine gastrointestinal glucagon-like immunoreactivity.

Authors:  J J Holst
Journal:  Diabetologia       Date:  1977-04       Impact factor: 10.122

View more
  27 in total

Review 1.  Type 2 diabetes mellitus: a possible surgically reversible intestinal dysfunction.

Authors:  Priscila C Sala; Raquel S Torrinhas; Steven B Heymsfield; Dan L Waitzberg
Journal:  Obes Surg       Date:  2012-01       Impact factor: 4.129

2.  Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes.

Authors:  D H Jensen; K Aaboe; J E Henriksen; A Vølund; J J Holst; S Madsbad; T Krarup
Journal:  Diabetologia       Date:  2012-05       Impact factor: 10.122

3.  Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.

Authors:  F K Knop; T Vilsbøll; S Madsbad; J J Holst; T Krarup
Journal:  Diabetologia       Date:  2007-01-16       Impact factor: 10.122

Review 4.  Pancreatic signals controlling food intake; insulin, glucagon and amylin.

Authors:  Stephen C Woods; Thomas A Lutz; Nori Geary; Wolfgang Langhans
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

5.  Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance.

Authors:  Marie Eriksen; David H Jensen; Siri Tribler; Jens J Holst; Sten Madsbad; Thure Krarup
Journal:  Diabetologia       Date:  2015-03-09       Impact factor: 10.122

6.  Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions.

Authors:  B Schjoldager; P E Mortensen; J Myhre; J Christiansen; J J Holst
Journal:  Dig Dis Sci       Date:  1989-09       Impact factor: 3.199

7.  Glicentin 1-61 probably represents a major fraction of glucagon-related peptides in plasma of anaesthetized uraemic pigs.

Authors:  F G Baldissera; J J Holst
Journal:  Diabetologia       Date:  1986-07       Impact factor: 10.122

Review 8.  Glucagon physiology and pathophysiology in the light of new advances.

Authors:  R H Unger
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

Review 9.  Do glucagonomas always produce glucagon?

Authors:  Nicolai Jacob Wewer Albrechtsen; Benjamin G Challis; Ivan Damjanov; Jens Juul Holst
Journal:  Bosn J Basic Med Sci       Date:  2016-02-01       Impact factor: 3.363

10.  Glucagon-related peptides in the human gastrointestinal mucosa.

Authors:  F G Baldissera; J J Holst
Journal:  Diabetologia       Date:  1984-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.